Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
One of the potential therapeutic advantages of stem cells is that they can regenerate. But, a new study, published May 11 in Nature, suggests that the longer…
By Mike O'Brien bio
Here is my periodic update prepared for interested HR professionals trying to deal with the complex American employment laws…
From - Diagnostic Testing & Emerging Technologies
The Xpert HCV Viral Load test (Cepheid, Sunnyvale, Calif.) for hepatitis C virus (HCV) has good accuracy for detecting viral RNA using whole blood from a finger stick…
From - Diagnostic Testing & Emerging Technologies
As the price of sequencing continues to drop and genomic testing in oncology continues to shift towards larger panels, physicians have self-reported difficulty in…
From - Diagnostic Testing & Emerging Technologies
The United States is falling behind national goals to identify patients unaware of their positive HIV status and link them to care…
From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) recently unveiled its FY 2015-2016: Regulatory Science Progress Report. The report, the second of its kind under the…
From - Diagnostic Testing & Emerging Technologies
Smartphone push-alert notification of troponin laboratory results allow physicians to discharge patients seen in the…